Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

News · September 26, 2018

IASLC WCLC 2018: IMpower132 Study Showcases Efficacy and Safety of Atezolizumab for Stage IV Non-Squamous NSCLC

Latest interim analysis reveals superior progression-free survival and hints at overall survival benefits with the addition of atezolizumab

PracticeUpdate Editorial Team

 

Further Reading